The isolation of human induced pluripotent stem cells (iPSCs) 1-3 offers a new strategy for modelling human disease. Recent studies have reported the derivation and differentiation of disease-specific human iPSCs 4-7 . However, a key challenge in the field is the demonstration of disease-related phenotypes and the ability to model pathogenesis and treatment of disease in iPSCs. Familial dysautonomia (FD) is a rare but fatal peripheral neuropathy, caused by a point mutation in the IKBKAP 8 gene involved in transcriptional elongation 9 . The disease is characterized by the depletion of autonomic and sensory neurons. The specificity to the peripheral nervous system and the mechanism of neuron loss in FD are poorly understood owing to the lack of an appropriate model system. Here we report the derivation of patient-specific FD-iPSCs and the directed differentiation into cells of all three germ layers including peripheral neurons. Gene expression analysis in purified FD-iPSC-derived lineages demonstrates tissuespecific mis-splicing of IKBKAP in vitro. Patient-specific neural crest precursors express particularly low levels of normal IKBKAP transcript, suggesting a mechanism for disease specificity. FD pathogenesis is further characterized by transcriptome analysis and cell-based assays revealing marked defects in neurogenic differentiation and migration behaviour. Furthermore, we use FD-iPSCs for validating the potency of candidate drugs in reversing aberrant splicing and ameliorating neuronal differentiation and migration. Our study illustrates the promise of iPSC technology for gaining new insights into human disease pathogenesis and treatment.
The isolation of human induced pluripotent stem cells (iPSCs) 1-3 offers a new strategy for modelling human disease. Recent studies have reported the derivation and differentiation of disease-specific human iPSCs [4] [5] [6] [7] . However, a key challenge in the field is the demonstration of disease-related phenotypes and the ability to model pathogenesis and treatment of disease in iPSCs. Familial dysautonomia (FD) is a rare but fatal peripheral neuropathy, caused by a point mutation in the IKBKAP 8 gene involved in transcriptional elongation 9 . The disease is characterized by the depletion of autonomic and sensory neurons. The specificity to the peripheral nervous system and the mechanism of neuron loss in FD are poorly understood owing to the lack of an appropriate model system. Here we report the derivation of patient-specific FD-iPSCs and the directed differentiation into cells of all three germ layers including peripheral neurons. Gene expression analysis in purified FD-iPSC-derived lineages demonstrates tissuespecific mis-splicing of IKBKAP in vitro. Patient-specific neural crest precursors express particularly low levels of normal IKBKAP transcript, suggesting a mechanism for disease specificity. FD pathogenesis is further characterized by transcriptome analysis and cell-based assays revealing marked defects in neurogenic differentiation and migration behaviour. Furthermore, we use FD-iPSCs for validating the potency of candidate drugs in reversing aberrant splicing and ameliorating neuronal differentiation and migration. Our study illustrates the promise of iPSC technology for gaining new insights into human disease pathogenesis and treatment.
Familial dysautonomia (FD), also known as hereditary sensory and autonomic neuropathy III (HSAN-III) or Riley-Day syndrome, is a fatal autosomal recessive disease characterized by the degeneration of sensory and autonomic neurons 8, 10 . The pathogenesis of the disease and its specificity to the peripheral nervous system are poorly understood. Most FD patients carry a point mutation in the I-k-B kinase complex-associated protein (IKBKAP) gene resulting in a tissue-specific splicing defect with various levels of exon 20 skipping and reduced levels of normal IKAP protein 8, 11 . Reduced IKAP protein levels are associated with a defect in cell motility 9 . However, it is unclear whether decreased cell motility is functionally related to the specific peripheral neuron pathology observed in FD. On the basis of the splicing defect, in vitro drug screens have been performed in patient lymphoblast cell lines to identify compounds that improve normal IKBKAP splicing and increase IKAP protein levels 12 . However, lack of access to tissues affected by FD, such as neural crest precursors and peripheral neurons, has hampered functional validation of candidate drugs and a systematic analysis of disease pathogenesis. Here we demonstrate the potential of human iPSC technology to model FD pathogenesis and treatment (Supplementary Fig. 1 ).
We obtained fibroblasts from a 10-year-old female FD patient and established two independent clones of FD-iPSCs (FD-4, FD-22) after transduction with lentiviral vectors encoding for OCT4 (also known as POU5F1), SOX2, KLF4 and c-MYC ( Fig. 1a -c). Further iPSCs clones were derived from two other FD patients (16- year-old male and 12-year-old female FD patients) and from non-affected control fibroblasts using the same procedure. The vector system used for iPSC generation allowed convenient monitoring of transgene expression by individual fluorescence tags by P2A technology 13 . All FD and control iPSCs used in this study showed silencing of the four transgenes, exhibited characteristic human embryonic stem cell (ESC) morphology, expressed pluripotency markers including Nanog, SSEA3, SSEA4, TRA-1-81 and had a normal karyotype ( Fig. 1b-f and Supplementary Figs 2 and 3 ). Pluripotent properties of FD-iPSCs were also assessed by monitoring the methylation status of the NANOG promoter ( Fig. 1g ), by global transcriptome analysis in comparison to FD-fibroblasts, human ESCs (line H9) and control-iPSC lines ( Fig. 1h and Supplementary Fig. 3 ), and by teratoma formation on intramuscular injection of undifferentiated FD-iPSCs into non-obese diabetic/severe combined immunodeficient (NOD-SCID) mice ( Fig. 1i ). Genetic identity was confirmed by DNA fingerprinting analysis for microsatellite markers (Supplementary Table  1 ). The genetic defect was confirmed as a homozygous 250716T . C mutation in the IKBKAP gene ( Fig. 1j ) known to induce tissuespecific skipping of exon 20. Gene expression analysis for IKBKAP revealed that FD-fibroblasts and FD-iPSCs express both the wildtype and the mutant IKBKAP transcript, although the ratio of normal to mutant transcript was higher in FD-iPSCs than in FD-fibroblasts ( Fig. 1k ).
The pluripotent nature of iPSCs offers the opportunity for probing the tissue specificity of the IKBKAP splicing defect in vitro. FD-and control-iPSCs (two clones each) were differentiated into five major tissues comprising all three embryonic germ layers. No reactivation of transgenes was observed in differentiated progeny ( Supplementary  Fig. 2 ). After directed differentiation towards central nervous system (CNS) 14 , peripheral nervous system 15 , haematopoietic 16 , endothelial 17 , and endodermal 18 precursors, iPSC derivatives were further enriched by prospective isolation using lineage-specific surface markers ( Fig. 2a-f ). Early neural differentiation was characterized by the formation of neural rosette structures in both FD-and control-iPSCs ( Supplementary Fig. 4 ). No major differences were observed in the efficiency of differentiation towards any of the five lineages comparing FD-versus control-iPSCs (data not shown). However, marked differences were observed for the ratio of normal:mutant transcript among the five FD-iPSCs-derived tissues ( Fig. 2a-f , insets). The mutant transcript predominated particularly in CXCR4 1 purified endodermal precursors (SOX17 1 ) and, to a lesser extent, in neural crest precursors (Fig. 2g ). The disease symptoms in FD are thought to be caused by loss of sufficient levels of normal IKBKAP transcript. Therefore, we next performed quantitative PCR with reverse transcription (qRT-PCR) analysis to determine the absolute levels of normal spliced IKBKAP transcript in each of the five FD-or control-iPSC-derived cell populations (Fig. 2h ). These data showed particularly low levels of normal IKBKAP transcript in FD-iPSC-derived neural crest precursors in vitro, compatible with the tissue-specific human pathology observed in FD patients. High levels of mutant IKBKAP expression in endodermal precursors are of interest in view of the debilitating gastrointestinal problems observed in FDalthough such symptoms are thought to be a consequence of a primary defect in the peripheral nervous system.
Directed differentiation of patient-specific iPSCs towards neural crest lineages, the primary tissue affected in FD, enables modelling functional aspects of pathogenesis in vitro. Neuropathological studies have demonstrated a marked depletion of autonomic and sensory neurons in FD patients. However, the cause for peripheral neuron loss in FD remains unclear, and there are at present no mouse models that faithfully replicate the disease. Mouse modelling in other neural crest disorders has identified several potential disease mechanisms, such as impaired neural precursor cell migration in Hirschsprung's disease 19 or degeneration of established neural crest tissues in Treacher Collins syndrome 20 . We explored the involvement of candidate disease mechanisms in FD by performing comparative transcriptome analysis of fluorescence-activated cell sorting (FACS)-purified FD-iPSC versus control-iPSC-derived neural crest precursors ( Fig. 3a and Supplementary Table 2 ; raw data of microarray data available at the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE17043). Among 48,000 probe sets, 35 transcripts were significantly increased and 54 transcripts decreased in FD-iPSC versus control iPSC-or ESC-derived neural crest precursors (foldchange $2-fold; corrected P value of 0.05). Differential expression of key transcripts from the microarray study was confirmed by qPCR analysis for neural crest precursors of both FD-iPSC clones ( Supplementary Fig. 5 ). Notably, among the 20 most decreased transcripts in FD neural crest precursors were many genes involved in peripheral neurogenesis and neuronal differentiation. Examples include SLC17A6 (also known as VGLUT2) expressed in sensory 
TRA-1-81 + g h 21 ). Of particular interest were the significant differences in ASCL1 (previously known as Mash1 in mice) expression between FD-and control-iPSC given the essential role of ASCL1 for the development of autonomic neurons during mouse development 21 . Differential expression of ASCL1 was further confirmed at the protein level by quantifying the percentages of ASCL1-immunoreactive cells (Fig. 3b ). The marked differences in neurogenesis were also reflected by a reduction in the percentage of spontaneously differentiating Tuj1 1 neurons in FD-iPSC-derived neural crest precursor cultures ( Fig. 3c ). Peripheral neurogenesis was not completely blocked, as FD-iPSCderived BRN3A 1 (also known as POU4F1 1 ) and peripherin 1 neurons were observed on further in vitro differentiation (Fig. 3c, inset) . These data indicate a defect in the propensity of FD-iPSC-derived neural crest precursors to undergo neuronal differentiation. Previous studies in IKBKAP-depleted or patient-specific fibroblasts indicated that reduced levels of normal IKBKAP are associated with defects in cell migration 9, 22 . Using a wound healing ('scratch') assay we observed a significant decrease in the migration of FD-iPSC-versus control-iPSCderived neural crest precursors (Fig. 3d ). FD-iPSC-derived neural crest precursors also showed a reduction in the number of paxillin 1 focal adhesions critical for cell spreading and migration (Fig. 3e ).
Our study shows defects in IKBKAP splicing, neurogenesis, and migration of FD-iPSC-derived neural crest precursors. Results were validated in several independent FD-iPSC clones (see Supplementary  Fig. 6 ) and compared to both non-affected control-iPSC and control human ESC cultures. These data demonstrate that FD-iPSC-derived neural crest precursors represent a powerful model system to probe disease pathogenesis, although larger sets of FD-iPSC lines may be useful to further validate disease phenotype.
Another key promise of human iPSC research is the use of patientspecific cells in drug discovery. Our study has demonstrated three easily quantifiable parameters of the disease state: a defect in IKBKAP splicing, decreased rate of neurogenesis, and reduced migration in FD-iPSC-derived neural crest precursors. We next tested whether exposure to candidate drugs can affect any of these three parameters. The plant hormone kinetin was previously shown to reduce levels of ANKRD38 is also known as KANK4; FLJ33790 is also known as KLHL35; FLJ25404 is also known as C16orf92; FLJ21986 is also known as C7orf58; KIAA0644 EntrezGene ID 9865; D4S234E EntrezGene ID 27065, HMP19 EntrezGene ID 51617. b, c, Representative images and quantifications of ASCL1 (b) and Tuj1 (c) expression in spontaneously differentiated neural crest cells derived from FD-iPSCs and C14-iPSCs. n 5 4; **P , 0.01; ***P , 0.001. The inset in c shows a representative image of putative sensory neuron progeny (BRN3A 1 and periperin 1 (Peri)) from FD-iPSCderived neural crest cells. d, e, Representative images of wound-healing assay (fixed at 48 h after scratching) (d) and paxillin staining (fixed at 1.5 h after plating) (e) of FD-iPSC-and C14-iPSC-derived neural crest cells. n 5 4; *P , 0.05. Quantification of paxillin staining was performed by counting the number of paxillin puncta marking focal adhesion complex. All values are mean and s.d. Scale bars, 50 mm. the mutant IKBKAP splice form in FD-derived lymphoblast cell lines 12 . Epigallocatechin gallate (ECGC) and tocotrienol have also been reported to effect splicing and the absolute levels of IKBKAP 23, 24 . Exposure of FD-iPSC-derived neural crest precursors to kinetin resulted in a marked reduction of the mutant IKBKAP splice form (Fig. 4a) . In contrast, no significant improvements in IKBKAP splicing were observed after ECGC or tocotrienol exposure ( Supplementary Fig. 7) . The kinetin-mediated decrease in mutant IKBKAP was associated with an increase in normal IKBKAP levels and the ratio of normal:mutant transcript (Fig. 4b ). No significant increase in normal IKBKAP transcript levels was observed after kinetin treatment of neural crest precursors derived from control iPSCs ( Supplementary Fig. 8 ). Although short-term (1 or 5 day) kinetin treatment of FD-iPSC-derived neural crest precursors had considerable effects on IKBKAP splicing, it did not result in a significant increase in the expression of neurogenic markers or improve migration behaviour ( Supplementary Figs 9 and 10 ). We next tested the effect of continuous (28 day) kinetin treatment of FD-iPSCs starting at the pluripotent stage 1 day before differentiation ( Supplementary  Fig. 11 ). Notably, continuous kinetin treatment induced a significant increase in the percentage of differentiating neurons and in the expression of key peripheral neuron markers such as ASCL1 and SCG10 at the neural crest precursor stage (Fig. 4c, d ). No significant increase was observed in FD-iPSC neural crest precursor cell migration ( Fig. 4e ), suggesting incomplete restoration of disease phenotype. These data demonstrate the feasibility of exploring disease mechanism and action of candidate drugs in FD-iPSCs. Although future studies will be required to define the developmental windows of kinetin action in greater detail, our data indicate that early stage long-term treatment may be particularly beneficial in FD patients.
Since the initial reports on human iPSC isolation 1-3 , several patient-specific iPSC lines have been developed [4] [5] [6] [7] . Modelling human disease in iPSCs has remained challenging owing to difficulties in directing iPSC fate and identifying disease-related behaviours. Previous reports have demonstrated the derivation of patient-specific motoneurons as an initial step in modelling amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) and dopamine neurons for modelling Parkinson's disease 4, 5, 7 . Although the study using SMA-iPSCs reported a potentially disease-related loss of cholinergic neurons 5 , the other studies did not observe 7 or did not report 4 any disease-related phenotypes. Interestingly, both SMA and FD are early onset disorders, suggesting that iPSC technology may be particularly suited to model developmental disorders. Here we extend the approach to modelling disease in the neural crest lineage and provide clear evidence of disease-related behaviours in FD-iPSCs. Although FD is a rare genetic disorder with an incidence of 1/3,600 live births among the Ashkenazi Jewish population (,600 registered patients worldwide 25 ), it provides a platform to demonstrate the potential of iPSC technology for exploring disease mechanism in a human genetic disorder. Studying aberrant tissue-specific IKBKAP splicing in iPSCs will be particularly attractive given the pluripotent nature and unlimited number of cells available for mechanistic studies and for high-throughput drug discovery. Our data on defects in neurogenic propensity and migration of FD-iPSC-derived neural crest precursors provide new insights into disease pathogenesis and suggest alternative functional assays for the identification and validation of candidate drugs. Furthermore, kinetin treatment illustrates the potential of iPSC technology for modelling therapeutic action in human neural disease in vitro using patient-specific cells.
METHODS SUMMARY
iPSC generation and differentiation. FD and control fibroblasts were obtained from Coriell and reprogrammed towards iPSCs using a lentiviral four factor protocol (OCT4, SOX2, KLF4 and c-MYC) described recently 13 . Undifferentiated human ESCs and iPSC lines were maintained on mitotically inactivated mouse embryonic fibroblasts (MEFs) in serum-replacement medium in the presence of 4 ng ml 21 FGF2 (ref. 15 ). For neural induction, human ESCs were plated on a confluent layer of irradiated stromal cells (MS-5) as described previously 15, 26 . After 3-4 weeks of differentiation, ESC progeny was triturated into single cells after Accutase dissociation (Innovative cell technologies) and labelled with antibodies for flow cytometry. Protocols for directed differentiation into all the other individual lineages are described in the Methods. Karyotype analysis and teratoma formation. Standard G-banding analysis was performed by the Memorial Sloan-Kettering Cancer Center molecular cytogenetics core laboratory as described previously 27 . For teratoma formation FD-iPSCs were injected into the hindlimb muscle of NOD-SCID Il2rg-null mice (Jackson Laboratory) and analysed histologically 4-6 weeks after injection. Animal studies were approved by MSKCC Institutional Animal Care and Use Committee. Molecular analyses. Total RNA was extracted using the RNeasy kit and DNase I treatment (Qiagen), and reverse transcribed (Superscript, Invitrogen). Primer sequences, cycle numbers, and annealing temperatures ( Supplementary Table 3) for IKBKAP correspond to those used previously 12 , the quantification of PCR bands was performed using ImageJ software (NIH) and the ratio of normal:mutant transcript was determined. qRT-PCR analysis was performed as described previously 28 . Gene expression microarray analysis was carried out by the Sloan-Kettering Institute genomics core laboratory using the human Illumina-12 and Illumina-6 platforms. Bisulphite sequencing analysis of the NANOG promoter was performed according to ref. 3 . Immunocytochemistry. Cells were fixed in 4% paraformaldehyde, permeabilized with Triton-X-100-containing buffer and stained with primary antibodies (list of antibodies provided in the Methods section). Appropriate fluorescentlabelled secondary antibodies (Molecular Probes) and 4,6-diamidino-2-phenylindole (DAPI) counterstaining was used for visualization.
METHODS
Human iPSC generation. Lentiviral vectors encoding human OCT4, SOX2, KLF4 and c-MYC under the transcriptional control of human phosphoglycerate kinase (PGK) promoter were constructed 13 . Overlapping PCR was used to generate bi-cistronic expression cassettes encoding vexGFP, mCitrine, mCherry and mCerulean linked by a P2A peptide preceded by a Gly-Ser-Gly linker to the complementary DNAs of human OCT4, SOX2, KLF4 and c-MYC, respectively, which were cloned in a lentiviral vector under the transcriptional control of human PGK promoter. Vector supernatants were produced as previously described 13 . Lentiviral vector supernatants were produced by triple co-transfection of the plasmid DNA encoding the vector, pCMVDR8.91 and pUCMD.G into 293T cells, filtered through a 0.22-mm pore-size cellulose acetate filter (Whatman) and concentrated by ultracentrifugation. Human FD and normal fibroblasts (GM04959, GM04589, GM04899, GM02341, GM02342 and GM023036) purchased from Coriell, and human fetal lung fibroblasts (MRC-5) purchased from ATCC (CCL-171), were seeded at 1.5 3 10 5 cells per well of a 6-well plate in EMEM supplemented with 10% FBS. The next day the fibroblasts were transduced with supernatants of the four lentiviral vectors in the presence of 4 mg ml 21 polybrene for ,16 h. Five days after transduction, fibroblasts were collected by trypsinization and plated at 2 3 10 4 cells per 60-mm dish on a feeder layer of mitomycin-C-treated MEFs (GlobalStem, Inc.). The next day, the medium was switched to human ESC medium supplemented with 6 ng ml 21 FGF2 and was replaced every day thereafter. Twenty days after transduction, colonies with human ESC morphology were mechanically dissociated and transferred into 24-well plates on MEFs. Cells were thereafter passaged with dispase and expanded to establish iPSC lines. Cell culture and differentiation. Undifferentiated human ESCs and iPSC lines were cultured on mitotically inactivated MEFs in a serum-replacement containing culture medium supplemented with 4 ng ml 21 FGF2 as used routinely for human ESC cultures 15, 26 . For neural induction, human ESCs were plated at 5-20 3 10 3 cells on a confluent layer of irradiated (50 Gy) stromal cells (MS-5) in 60-mm cell culture plates in KSR medium 26 . After 16 days in serum-replacement medium, cultures were switched to N2 medium. Medium was changed every 2-3 days, and growth factors were added at the following concentrations as described previously: 200 ng ml 21 SHH, 100 ng ml 21 FGF8, 20 ng ml 21 brainderived neurotrophic factor (BDNF) (all R&D Systems), and 0.2 mM ascorbic acid (Sigma-Aldrich). Rosette structures were collected mechanically at day 14-20 of differentiation (termed passage 0; P0) and gently replated on 15 mg ml 21 polyornithine/1 mg ml 21 laminin (PO/Lam)-coated culture dishes in N2 medium (termed passage 1; P1). P1 cultures were supplemented with FGF2, ascorbic acid and BDNF or any alternative growth factor conditions as listed in the main text. After 6-7 days of P1 culture, cells were triturated into single cells after exposure to Accutase (Innovative cell technologies, Inc., 10 min at incubator) and labelled with antibodies for flow cytometry. FACS sorting (HNK1 (ref. 15 ), Sigma; or Forse1 (ref. 14) , DSHB) was performed on a MoFlo (Dako). Sorted cells were plated on culture dishes precoated with PO/Lam and 10 ng ml 21 fibronectin (PO/Lam/Fib). Human ESC-NCSCs (neural crest stem cells) were maintained in N2 medium supplemented with 20 ng ml 21 FGF2 and 20 ng ml 21 EGF changed every 2-3 days and passaged every 7-8 days, as previously described. For differentiation of ESC-NCSCs towards peripheral neurons, FGF2/EGF-expanded ESC-NCSCs were subjected to mitogen withdrawal in medium supplemented with BDNF, GDNF, NGF and dibutyryl-cAMP. Formation of human embryoid bodies for haematopoietic 16 and endothelial 17, 29 differentiation was performed as previously described. Intact human ESC or iPSC colonies were collected and plated in low-attachment dishes (Corning) with DMEM, 20% Hyclone serum, 1% non-essential amino acids, 1 mM L-glutamine (Glut), 0.1 mM b-mercaptoethanol (MTG), 50 ng ml 21 BMP4, 50 ng ml 21 VEGF. Every other day, medium was changed with serum-free medium (Sigma) supplemented with Glut, non-essential amino acids, MTG, and the following cytokines: 5 ng ml 21 BMP4, 10 ng ml 21 bFGF, 20 ng ml 21 VEGF, 20 ng ml 21 SCF, 20 ng ml 21 Flt3L (also known as FLT3LG), and 20 ng ml 21 TPO. Cells are dissociated with trypsin for 10 min in incubator. Subsequently, cells are passed through a 22G needle 3-4 times and through a 40-mm strainer. Embryoid-body-derived cells were plated into semi-solid culture (StemCell Technologies) for further differentiation. For haematopoietic cell, 0.05-0.1 million cells per 35-mm dish were plated at day 10 of embryoid body culture; for endothelial differentiation, 0.1-0.2 million cells per 35-mm dish were plated at day 5 of embryoid body culture. Endothelial cells were obtained after seeding of the blast-like colony (at day 5-6 of methylcellulose culture) onto a matrigelcoated plate in EBM2 medium (Lonza). After 3-4 passages, human ESC and iPSC-derived endothelial cells were sorted for CD144 (VE-cadherin) antibody (BD Biosciences). Haematopoietic cells (at day 14 of methylcellulose culture) were collected and sorted for CD45 antibody (BD Biosciences). For endodermal neural crest cell from (H9 and C14-iPSC) versus FD-iPSC was performed using the Linear Models for Microarray Data package (LIMMA) available through Bioconductor. Genes found to have an adjusted P-value , 0.05 and a fold change greater than two were considered significant. Some of the descriptive microarray data analyses and presentation was performed using a commercially available software package (Partek Genomics Suite (version 8.4.17)). Genomic DNA (gDNA) is isolated using Qiagen kit from patient fibroblast lines and iPSC clones. For validation of sequencing, conventional PCR was used (the conditions are in Supplementary Table 3 ). Microsatellite analysis of gDNA was performed at the Rockefeller genomic core facility. For bisulphite genomic sequencing, gDNA samples from FD-fibroblast and FD-iPSC were extracted. Bisulphite treatment of gDNA was carried out using a CpGenome DNA Modification Kit (Chemicon) according to the manufacturer's protocol. Converted gDNA was amplified by PCR using NANOG primer sets 6 . PCR products were gel-purified and cloned into bacteria using TOPO TA cloning (Invitrogen). Bisulphite conversion efficiency of non-CpG cytosines ranged from 80% to 99% for individual clones for each sample. 
